2023-03-31-accounts

P, PROSTATE CANCER UK ANNUAL REPORT AND FINANCIAL STATEMENTS 2022/23

As a result ofthe above, the Trus test.	tee	s consider that Prostate Cancer UK satisfies the		public	benefit
Principal risks and uncertainties
The principal risks to which the charity is exposed, as identified by the Trustees, are			regularly
reviewed and systems have been	established to mitigate them. A risk register summarises				the
principal risks facing the charity, graded according to their likelihood and impact, and				identifies
actions to manage them. The register has been redesigned to align with the new organisational
strategy, with individual risks and	their mitigations set out under one overall risk and		each ofthe
Pillars and Drivers. It is reviewed	and updated by the Leadership Team each month,			and reviewed
twice a year by the Finance, Risk	and Audit Committee. The Board of Trustees reviews the				register
annually, but any 'red light' issues	are brought to their attention as they arise.
Pillar 1 - That we fail to	~	We will develop specific messaging and training		for
reach and activate more		volunteers based on their geographical location
men into making an	~	We will use data and evidence available to us to
informed choice about their		triangulate to those areas most in need
prostate cancer risk		We will ensure that any insights we gather are
		communicated in a clear and helpful way.
Pillar 2 —That we fail to	~	We will have clear action plans and measurement		for
reduce health inequalities		each commitment
	~	We are having honest and open conversations	within
		Black communities
	~	We will deploy targeted programmes ofactivity.
Pillar 3—That we fail to	~	We will issue clear guidance around the funding		process
accelerate earlier		to ensure applications are of high quality and ready to
diagnosis and the delivery		fund.
of better, more precise
iraairnani.

				We will develop compelling case studies that emphasise	We will develop compelling case studies that emphasise
				the importance and impact ofresearch to inspire
				audiences
				We will work with partners to ensure that early diagnosis
				trials and programmes are fully funded.
Pillar 4 —That we fail to				We will increase the provision of individual and group
transform		the experience		clinical supervision
and support for			men with	We will improve accessibility to our services
prostate cancer			to live and	We will innovate and improve our processes in line with
die well				feedback to improve the services we offer.
Driver	1 —That		trust in our	Trust in our brand remains high
brand	comes into disrepute			Key stakeholder relationships will be fully vetted to
				ensure they align with our values
				Our fundraisers are inducted into the Institute of Funding
				code ofpractice
				Risks assessments and health and safety plans are put
				in place ahead ofany event we' re involved with.
Driver	2 —That		we fail to	We will use data, analysis and insight to drive our
generate		sufficient income		decision making
to fund our activities				We are investing for growth in areas that are new to	us
				We will ensure we' re maximising all revenue streams
				We will generate net income growth through strong cost
				and margin controls
				We will innovate the products we offer to ensure we
				engage with a wide ranging audience for longer.
Driver	3—That		we are	We have strong mitigation plans in place to manage
unable	to recruit		or retain	adverse risks across retention, recruitment, inclusion,
staff				health and safety and safeguarding
				We have developed an EDI plan and set up People
				Networks to engage with staff and promote diversity	and
				inclusion across our organisation
				We have introduced a new pay framework and hybrid
				working policy to attract candidates and to ensure staff
				are remunerated in line with the market average.
Driver	4 —That		we are	We have an insight strategy and data strategy which	is
unable	to use the data and			reviewed quarterly by the leadership team
insight	available		to us to	A roadmap and best practices have been introduced	and
make	accurate		decisions	are regularly reviewed.

			Unrestricted	Restricted	Total	Total
			Funds	Funds	2023	2022
		Notes	K'000	K'000	K'000	E'000
INCOME FROM
Donations and legacies			28,687	3,999	32,686	34,951
Other trading activities			541		541	419
Investments —bank	interest		722		722	73
Total			29950	3,999	33949	35,443
EXPENDITURE ON
Raising funds			9,420		9,420	9,375
Charitable activities			22,415	2,506	24,921	15,685
Total			31,835	2,506	34,341	25,060
Net income/(expenditure)		4	(1,885)	1,493	(392)	10,383
Transfers between funds		18	3,224	(3,224)
Net movement in funds			1,339	(1,731)	(392)	10,383
Reconciliation offunds:
Total funds brought	forward		27,142	9,196	36,338	25,955
Total funds carried	forward	'l8	28,481	7,465	35,946	36,338

				Unrestricted	Restricted	Total	Total
				Funds	Funds	2023	2022
				R'000	R'000	R'000	R'000
INCOME FROM
Donations and	legacies			28,964	3,999	32,963	35,136
Investments				722		722	73
Total				29,686	3,999	33,685	35,209
EXPENDITURE	ON
Raising funds				9,160		9,160	9,144
Charitable activities				22,411	2,506	24,917	15,682
Total				31,571	2,506	34,077	24,826
Net income/(expenditure)				(1,885)	1,493	(392)	10,383
Transfers between		funds		3,224	(3,224)
Net movement	in funds			1,339	(1,731)	(392)	10,383
Reconciliation	of	funds:
Total funds brought			forward	27,142	9,196	36,338	25,955
Total funds carried			forward	28,481	7,465	35,946	36,338

Balance sh	eets		as at	31 March 20	23
						GROUP		CHARITY
					Notes	2023	2022	2023	2022
						K'000	8'000	f'000	6'000
Fixed assets
Intangible assets					10		9		9
Tangible assets					11	120	313	120	313
Investments					12
Total fixed assets						120	322	120	322
Current assets
Stocks					13	103	93
Debtors					14	12,099	12,751	12,192	12,891
Short-term deposits						25,894	20,589	25,894	20,589
Cash at bank	and	in	hand			19,534	23,355	19,470	23,266
Total current	assets					57,630	56,788	57,556	56,746
Liabilities:
Creditors: Amounts			falling	due within one	15	9,751	11,734	9,677	11,692
year
Net current assets						47,879	45,054	47,879	45,054
Total assets	less	current		liabilities		47,999	45,376	47,999	45,376
Creditors: Amounts			falling	due after more
than one year					16	12,053	9,038	12,053	9,038
Net assets						35,946	36,338	35,946	36,338
Funds:
Restricted income			funds		18	7,465	9,196	7,465	9,196
Unrestricted	funds
General					18	28,361	23,449	28,361	23,449
Designated					18	120	3,693	120	3,693
						28,481	27,142	28,481	27,142
Total funds						35,946	36,338	35,946	36,338

					2023	2023	2022	2022
				Notes	8'000	6'000	R'000	R'000
Cash flows from operating		activities:
Net cash	provided by (used in) operating
activities				22		762		9,456
Cash flows from investing		activities:
Interest					722		73
Purchase	offixed assets						(40)
Net cash activities	provided by (used in) investing					722		33
Change in cash and cash		equivalents	in			1,484		9,489
the reporting period
Cash and beginning	cash equivalents ofthe reporting	at the period				43,944		34,455
Cash and cash equivalents the reporting period		at the end	of			45,428		43,944
Changes	in net debt:
Cash and	cash equivalents	at start ofyear						43,944
Cash flows								1,484
Cash and	cash equivalents	at end ofyear						45,428

					Income	Income			2023	202
					Unrestricted	Restricted		Total	income	Total
					R'000		6'000		8'000	R'000
Individual	donors and legacies				16,105		61		16,166	16,006
Community		and events			10,232				10,232	12,323
Corporate	donors				1,487		305		1,792	2,469
Major donors and charitable			trusts		781		1,183		1,964	1,671
Donated	goods and services				82				82	73
Government		grants					2,450		2,450	2,409
					28,687		3,999		32,686	34,951
Ofwhich	in	2022:
Restricted										4,217
Unrestricted										30,734
										34,951
The income		from government		grants	relates to E2,450k		from the	Medical Research		Council
for research		(2022:E509k), the		NHS	Risk Checker Campaign ANIL (2022:E1,899k),					and the
Coronavirus		Job Retention Scheme			ANIL (2022:f1k).
					Expenditure	on
					raising funds				2023	2022
					Direct	Support			Total	Total
					costs		costs		costs	costs
					R'000		R.'000		R'000	R'000
Individual	donors and legacies				4,713		735		5,448	5,703
Community		and events			2,324		362		2,686	2,270
Corporate	donors				598		93		691	758
Major donors and charitable			trusts		319		50		369	444
Trading					226				226	200
					8,180		1,240		9,420	9,375

					2023	2022
					Total	Total
					R'000	8'000
Turnover					541	419
Cost ofgoods	sold				(260)	(219)
Gross profit					281	200
Administrative	expenses				(148)	(168)
Net profit					133	32
Income transferred		by Gift Aid			(133)	(32)
Retained in subsidiary
					2023	2022
					Total	Total
					F'000	E'000
Total current assets		as at 31 March			295	248
Total current	liabilities as		at	31	(295)	(248)
March
Net assets held as		at 31 March

4 Net income for the year	4 Net income for the year	4 Net income for the year
This is stated after charging:
			2023	2022
			R'000	f'000
Depreciation and amortisation			202	261
Auditor's	remuneration	—audit services	39	34
Auditor's	remuneration	—other services	4	4
Operating	lease rentals	—property	461	510

5 Charitable activities
			2023	2022
	Direct	Support	Total costs	Total
	costs	costs
	R'000	R'000		R'000
Research	9,991	259	10,250	1,528
Support and influencing	3,128	1,273	4,401	3,539
Awareness	7,788	2,482	10,270	10,618
	20,907	4,014	24,921	15,685

6 Grants awarded	6 Grants awarded
Grant commitments		comprise	research		commitments				and	programme	commitments.
Research	grants are awarded		to fund	researchers			in	the	key areas of better		treatment	and
better diagnosis in line		with our	Research strategy.
			2023			2022
			Total			Total		Better		Better	Smarter
								Treatment		Diagnosis	Data
Research	grants were	awarded	R'000			R'000
to the following institutions:
				2,550
Imperial College London
Institute ofCancer Research				2,013		128
University	ofGlasgow			1,749
University	College London			690
Newcastle	University			513
University	ofSheffield			447
Swansea	University			402
University	ofOxford			299
University	ofEast Anglia			292
University	of Nottingham			259
University	of Bristol			245
University	of Manchester			118		546
Queen's	University Belfast					284
				9,577		958

				2023	2022
Reconciliation	of	research grants payable:		R'000	E'000
Commitments	at 1	April		16,544	20,318
Commitments	made in the year			9,577	958
Grant adjustments		and cancellations		(226)	(115)
Grants paid during		the year		(5,509)	(4,617)
Commitments	at	31 March		20,386	16,544
				2023	2022
Outstanding	research commitments		at 31 March are payable	f'000	E'000
as follows:
Within one year (Note 15)				8,333	7,531
After more than one year (Note 16)				12,053	9,013
				20 386	16,544

				2023	2022
Reconciliation	of	programme	grants payable:	K'000	K'000
Commitments	at 1	April			12
Commitments	made in the year
Grant adjustments		and cancellations			(3)
Grants paid during		the year			(9)
Commitments	at 31 March

The average full-time equi was:	valent number of persons employ	ed by the group duri	ng the y
		2023	2022
Fundraising		49	47
Research		8	8
Support and Influencing		41	36
Communications		62	52
Finance, IT 8 Technology,	People and Facilities	41	38
		201	181

The average number ofe the year was as follows:	mployees (head count based on nu	mber ofstaff employe	d) during
		2023	2022
Fundraising		52	49
Research		8	8
Support and Influencing		44	43
Communications		65	54
Finance, IT &Technology,	People and Facilities	41	36
		210	190

nts paid in r	espec	t ofemployees were:
			2023	2022
			6'000	8'000
Salaries and	wages		8,236	6,654
Social security costs			893	704
Pension costs			946	829
Termination	payments		45	11
Total emoluments		ofemployees	10,120	8,198
Agency staff			282	172
			10,402	8,370

The number ofemployees	whose emoluments	for the year were over f60,000 after salary	for the year were over f60,000 after salary
sacrifice was:
		2023	2022
f60,001 to 270,000		10
f70,001 to 280,000
280,001 to F90,000
f90,001 to F100,000
f110,001 tof120,000

The breakdow	n of	support co	sts and how	these are al	located is sho	wn below.
					2023	2022
			Raising	Charitable	Total costs	Total costs
			funds	activities
			f.'000	R'000	R'000
Staff and similar			722	2,336	3,058
Supplies and	services		202	656	858	802
Premises costs			279	903	1,182	1,139
Depreciation			26	86	112	160
Governance	costs			33	44
			1,240	4,014	5,254	4,412
Governance	costs	comprise:			2023	2022
					Total costs	Total costs
					K'000	F'000
Audit fees					39	34
Trustee indemnity		insurance			5	5
					44	39

10Intangible fixed assets —Group and	Charity
	Software
Cost	8'000
At 1 April 2022	246
Disposal
Additions
At 31 March 2023	246
Amortisation
At 1 April 2022	237
Disposal
Charge for the year
At 31 March 2023	246
Net book value
Net book value at 31 March 2022
Net book value at 31 March 2023

	Lease	Fixtures	Computer	Computer	Total
	Improvements	and	equipment	and
		fittings	website
			development
Cost	R'000	6'000		R'000	6'000
At 1 April 2022	601	584		1,161	2,346
Additions
Disposals		(50)		(470)	(520)
At 31 March 2023	601	534		691	1,826
Depreciation
At 1 April 2022	524	583		926	2,033
Disposals		(50)		(470)	(520)
Charge for the year	62	1		130	193
At 31 March 2023	586	534		586	1,706
Net book value
Net book value at 31 March	77			235	313
2022
Net book value at 31 March	15			105	120
2023

Group		Charity
2023	2022	2023	2022
F'000	8'000	8'000	F'000
103	93

14Debtors
			Group		Charity
			2023	2022	2023	2022
			R'000	R'000	R'000	R'000
Trade debtors			2,351	1,814	2,224	1,760
Amounts due from subsidiary		undertaking			220	205
Prepayments			960	1,218	960	1,207
Accrued income			1,449	1,633	1,449	1,633
Other debtors			150	158	150	158
			4,910	4,823	5,003	4,963
Movember Foundation	accrued income		7,189	7,928	7,189	7,928
Total debtors			12,099	12,751	12,192	12,891

15Creditors —falli	ng due within o	ne year
		Group		Charity
		2023	2022	2023	2022
		f'000	8'000	F'000	F'000
Trade creditors		531	2,990	508	2,968
Research commitments		8,333	7,531	8,333	7,531
Other taxes and social	security	271	266	257	261
Accruals and deferred	income	458	473	446	458
Other creditors		158	474	133	474
		9,751	11,734	9,677	11,692

				Group		Charity
				2023	2022	2023	2022
				8'000	8'000	F'000	F'000
Balance	at 1 April			9		9
Amounts	released	to incoming	resources	(9)		(9)
Amount	deferred	in the year
Balance	at 31 March

6Creditors —falling due after	more than one year
	Group		Charity
	2023	2022	2023	2022
	8'000	8'000	E'000	E'000
Research commitments	12,053	9,013	12,053	9,013
Other creditors		25		25
	12,053	9,038	12,053	9,038

17Analysis of	group net assets	between fu	nds
		General	Designated	Restricted	Total funds
		funds	funds	funds
		R'000	R'000	R'000	R'000
Fixed assets (Note 10and 11)			120		120
Research designated	funds
Current assets		48,345		9,285	57,630
Liabilities due within	one year	(9,014)		(737)	(9,751)
Liabilities due after more than one year		(10,970)		(1,083)	(12,053)
Net assets at 31 March		28,361	120	7,465	35,946

		As at	Incoming	Outgoing	Transfers	As at
		01/04/2022				31/03/2023
		6'000	6'000	K'000	R'000	R'000
Restricted funds:
Movember Foundation		6,046		(678)		5,368
Other restricted funds:
General research		2,678	3,257	(902)	(3,009)	2,024
Specialist Nurses Service		160	328	(488)
Other restricted funds		312	414	(438)	(215)	73
Total other restricted	funds	3,150	3,999	(1,828)	(3,224)	2,097
Total restricted funds		9,196	3,999	(2,506)	(3,224)	7,465
Unrestricted funds		23,449	29,950	(28,262)	3,224	28,361
Designated funds:
Fixed asset reserves		322		(202)		120
Research designated	funds	3,371		(3,371)
Total designated funds		3,693		(3,573)		120
Total unrestricted funds		27,142	29,950	(31,835)	3,224	28,481
Total funds		36,338	33,949	(34,341)		35,946

Movember	Movember Foundation income from its campaigns,	Movember Foundation income from its campaigns,
Foundation	restricted	to spend on research and survivorship
	services	for men with prostate cancer.
General research	Funding	received to support either specific research
	awards or to be put towards other unfunded
	research	activity.
Specialist Nurses	Funding	for the Specialist Nurses Service to
Service	increase	access and support for men and their
	families	affected by prostate cancer.

roup has commitments under operating lease :	s due within the periods stated
	Property
	2023	2022
	R'000	F'000
Less than one year	439	612
Twn -five votre	2,663	151
Greater than five years	1,147
	4,249	763

Reconcilia activities.	tio	n ofne	t	incom	e/(expenditur	e) to net cash inflow from	operating
							2023	2022
							6'000	E'000
Net income/(expenditure)				for	the reporting	period (as per the	(392)	10,383
statement	of	financial	activities)
Adjustments		for:
Dividends	and interest						(722)	(73)
Depreciation		charges					203	261
Disposal								13
(Increase)	in	stocks					(10)	(40)
Decrease	in	debtors					651	1,213
Increase/(decrease)			in	creditors			1,032	(2,301)
Net cash	used in operating				activities		762	9,456

			Income	Income		2022
			Unrestricted		Restricted	Total income
			K'000		f'000	K'000
Individual	donors and legacies		15,652		354	16,006
Community	and events		12,322		1	12,323
Corporate	donors		2,101		368	2,469
Major donors and charitable		trusts	586		1,085	1,671
Donated goods and services			73			73
Government grant					2,409	2,409
			30,734		4,217	34,951
			Expenditure	on	raising funds	2022
			Direct costs		Support costs	Total costs
			K'000		E'000	K'000
Individual	donors and legacies		5,004		699	5,703
Community	and events		1,992		278	2,270
Corporate	donors		665		93	758
Major donors and charitable		trusts	390		54	444
Trading			200			200
			8,251		1,124	9,375

Note 5 - Charitable activities
			2022
	Direct	Support	Total costs
	costs	costs
	f'000	R'000	8'000
Research	1,308	220	1,528
Support and influencing	2,536	1,003	3,539
Awareness	8,553	2,065	10,618
	12,397	3,288	15,685

				2022
		Raising funds	Charitable	Total costs
			activities
		E'000	6'000	F'000
Staffand similar costs		579	1,693	2,272
Supplies and	services	204	598	802
Premises costs		290	849	1,139
Depreciation		41	119	160
Governance	costs	10	29	39
		1,124	3,288	4,412

Note 17 - Analysis	ofgroup net assets	between funds
		General funds	Designated	Restricted	Total funds
			funds	funds	2022
		F'000	R'000	F'000	F'000
Fixed assets (Note 10and 11)			322		322
Research designated	funds		3,371		3,371
Current assets		27,677		25,740	53,417
Liabilities due within	one year	(4,203)		(7,531)	(11,734)
Liabilities due after more than one year		(25)		(9,013)	(9,038)
Net assets at 31 March		23,449	3,693	9,196	36,338

		As at	Incoming	Outgoing	Transfers	As at
		1/04/2021				31/03/2022
		f.'000	6'000	8'000		6'000
Restricted funds: Movember
Foundation		6,018		28		6,046
Other restricted funds:
General research		1,263	1,415			2,678
IT architecture project		123		(123)
Specialist Nurses Service		181	689	(710)		160
NHS Funded Projects			1,899	(1,899)
Other restricted funds		105	214	(7)		312
Total other restricted	funds	1,672	4,217	(2,739)		3,150
Total restricted funds		7,690	4,217	(2,711)		9,196
Unrestricted funds		13,509	31,226	(21,259)	(27)	23,449
Designated funds:
Fixed asset reserves		556		(261)	27	322
Research designated	funds	4,200		(829)		3,371
Total designated funds		4,756		(1,090)	27	3,693
Total unrestricted funds		18,265	31,226	(22,349)		27,142
Total funds		25,955	35,443	(25,060)		36,338

prostatacancaruKorg Prostate Cancer UK @ProstateUK prostat•conc•ruk in Pro8tat8 Can¢•r UK , PROSTATE CANCER UK